Suppr超能文献

早期适应性自然杀伤细胞扩增与多发性骨髓瘤自体移植后复发减少相关。

Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma.

机构信息

Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Transplant Cell Ther. 2021 Apr;27(4):310.e1-310.e6. doi: 10.1016/j.jtct.2020.10.023. Epub 2020 Dec 17.

Abstract

Adaptive natural killer (NK) cells are long-lived and exhibit properties of immunologic memory against cytomegalovirus (CMV). We previously reported that expansion of adaptive NK cells after CMV reactivation in recipients of allogeneic hematopoietic cell transplantation (HCT) was associated with a lower rate of relapse of acute myelogenous leukemia. In the present study, we examined the impact of adaptive NK cell expansion in a cohort of 110 individuals who underwent autologous HCT (AHCT) for a lymphoid malignancy (lymphoma or multiple myeloma [MM]). In this cohort, higher absolute numbers of adaptive NK cells (>1.58/μL) at day 28 post-AHCT were associated with significantly decreased risk of relapse in patients with MM. No significant association was seen in patients with lymphoma. Further stratification of MM patients by CMV serostatus found a strong protective effect of adaptive NK cells only in CMV-seropositive individuals. These findings suggest that strategies to increase adaptive NK cells after AHCT may be a therapeutic option in patients with MM.

摘要

适应性自然杀伤 (NK) 细胞寿命长,并具有针对巨细胞病毒 (CMV) 的免疫记忆特性。我们之前报道过,异基因造血细胞移植 (HCT) 受者中 CMV 再激活后适应性 NK 细胞的扩增与急性髓细胞白血病 (AML) 复发率降低有关。在本研究中,我们在 110 名接受自体 HCT (AHCT) 治疗的淋巴恶性肿瘤(淋巴瘤或多发性骨髓瘤 [MM])患者队列中检查了适应性 NK 细胞扩增的影响。在该队列中,AHCT 后 28 天适应性 NK 细胞的绝对数量较高 (>1.58/μL) 与 MM 患者的复发风险显著降低相关。在淋巴瘤患者中未观察到显著相关性。对 MM 患者按 CMV 血清状态进一步分层发现,适应性 NK 细胞仅在 CMV 血清阳性个体中具有强烈的保护作用。这些发现表明,AHCT 后增加适应性 NK 细胞的策略可能是 MM 患者的一种治疗选择。

相似文献

1
Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma.
Transplant Cell Ther. 2021 Apr;27(4):310.e1-310.e6. doi: 10.1016/j.jtct.2020.10.023. Epub 2020 Dec 17.
2
CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2022 Jun;28(6):343.e1-343.e4. doi: 10.1016/j.jtct.2022.03.003. Epub 2022 Mar 8.
4
CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.
Leukemia. 2016 Feb;30(2):456-63. doi: 10.1038/leu.2015.260. Epub 2015 Sep 29.
9
Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.
Front Immunol. 2018 Mar 1;9:389. doi: 10.3389/fimmu.2018.00389. eCollection 2018.

引用本文的文献

1
Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic Criteria.
Mediterr J Hematol Infect Dis. 2025 Jan 1;17(1):e2025006. doi: 10.4084/MJHID.2025.006. eCollection 2025.
2
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.
Exp Hematol Oncol. 2024 Nov 13;13(1):114. doi: 10.1186/s40164-024-00578-4.
3
Adaptive natural killer cell expression in response to cytomegalovirus infection in blood and solid cancer.
Heliyon. 2024 Jun 6;10(11):e32622. doi: 10.1016/j.heliyon.2024.e32622. eCollection 2024 Jun 15.
4
Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma.
Front Cell Dev Biol. 2024 Feb 12;12:1359084. doi: 10.3389/fcell.2024.1359084. eCollection 2024.
5
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.
Front Oncol. 2023 Oct 2;13:1240966. doi: 10.3389/fonc.2023.1240966. eCollection 2023.
6
Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT.
Blood Adv. 2023 Oct 10;7(19):5784-5798. doi: 10.1182/bloodadvances.2022008952.
7
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
Blood Rev. 2023 Jul;60:101073. doi: 10.1016/j.blre.2023.101073. Epub 2023 Mar 12.
8
Metabolic regulation of NK cell function: implications for immunotherapy.
Immunometabolism (Cobham). 2023 Jan 23;5(1):e00020. doi: 10.1097/IN9.0000000000000020. eCollection 2023 Jan.

本文引用的文献

1
Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming.
J Clin Invest. 2019 Jun 18;129(9):3770-3785. doi: 10.1172/JCI125916.
2
Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients.
BMC Cancer. 2019 Apr 5;19(1):316. doi: 10.1186/s12885-019-5529-0.
3
Adaptive NK cell reconstitution is associated with better clinical outcomes.
JCI Insight. 2019 Jan 24;4(2):e125553. doi: 10.1172/jci.insight.125553.
5
Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37.
Cancer Immunol Res. 2018 Jul;6(7):766-775. doi: 10.1158/2326-6066.CIR-17-0498. Epub 2018 May 21.
8
Adaptive NK cells can persist in patients with mutation depleted of stem and progenitor cells.
Blood. 2017 Apr 6;129(14):1927-1939. doi: 10.1182/blood-2016-08-734236. Epub 2017 Feb 16.
9
Identification of Human Memory-Like NK Cells.
Curr Protoc Cytom. 2017 Jan 5;79:9.50.1-9.50.11. doi: 10.1002/cpcy.13.
10
Acquired somatic mutations in PNH reveal long-term maintenance of adaptive NK cells independent of HSPCs.
Blood. 2017 Apr 6;129(14):1940-1946. doi: 10.1182/blood-2016-08-734285. Epub 2016 Nov 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验